CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica — Oct 10th, 2024

Charles River Laboratories International, Inc. CRL has entered into an agreement with H. Lundbeck A/S (Lundbeck) — a Denmark-based global pharmaceutical company focused on neurological and psychiatric disorders. The collaboration will use Logica, an offering from Charles River and Valo H...

CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch — Oct 18th, 2024

Charles River Laboratories International, Inc. CRL recently launched its latest Retrogenix Non-Human Protein Library. This non-human protein library will help biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species...

CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica — Oct 10th, 2024

Charles River Laboratories International, Inc. CRL has entered into an agreement with H. Lundbeck A/S (Lundbeck) — a Denmark-based global pharmaceutical company focused on neurological and psychiatric disorders. The collaboration will use Logica, an offering from Charles River and Valo H...

CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch — Oct 18th, 2024

Charles River Laboratories International, Inc. CRL recently launched its latest Retrogenix Non-Human Protein Library. This non-human protein library will help biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species...

CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch — Oct 18th, 2024

Charles River Laboratories International, Inc. CRL recently launched its latest Retrogenix Non-Human Protein Library. This non-human protein library will help biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species...

Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease — Oct 2nd, 2024

Logica®, an offering from Charles River and Valo Health, will be leveraged to progress Lundbeck’s research into disorders of the central nervous system WILMINGTON, Mass., October 02, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced an ag...

CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica — Oct 10th, 2024

Charles River Laboratories International, Inc. CRL has entered into an agreement with H. Lundbeck A/S (Lundbeck) — a Denmark-based global pharmaceutical company focused on neurological and psychiatric disorders. The collaboration will use Logica, an offering from Charles River and Valo H...

Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call — Oct 16th, 2024

WILMINGTON, Mass., October 16, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2024 financial results on Wednesday, November 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednes...

Charles River Provides Translational Expertise at Neuroscience 2024 — Oct 3rd, 2024

WILMINGTON, Mass., October 03, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18 scientific posters, both independently and collaboratively with clients, at Neuroscience 202...

Charles River Launches New Retrogenix® Non-Human Protein Library — Oct 17th, 2024

First-in-class in vitro library assesses off-target binding to de-risk in vivo studies WILMINGTON, Mass., October 17, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Retrogenix® Non-Human Protein Library. The non-human p...

Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease — Oct 2nd, 2024

Logica®, an offering from Charles River and Valo Health, will be leveraged to progress Lundbeck’s research into disorders of the central nervous system WILMINGTON, Mass., October 02, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced an ag...

Charles River Launches New Retrogenix® Non-Human Protein Library — Oct 17th, 2024

First-in-class in vitro library assesses off-target binding to de-risk in vivo studies WILMINGTON, Mass., October 17, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Retrogenix® Non-Human Protein Library. The non-human p...

Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call — Oct 16th, 2024

WILMINGTON, Mass., October 16, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2024 financial results on Wednesday, November 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednes...

Charles River Launches New Retrogenix® Non-Human Protein Library — Oct 17th, 2024

First-in-class in vitro library assesses off-target binding to de-risk in vivo studies WILMINGTON, Mass., October 17, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Retrogenix® Non-Human Protein Library. The non-human p...

Charles River Launches New Retrogenix® Non-Human Protein Library — Oct 17th, 2024

First-in-class in vitro library assesses off-target binding to de-risk in vivo studies WILMINGTON, Mass., October 17, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Retrogenix® Non-Human Protein Library. The non-human p...

CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch — Oct 18th, 2024

Charles River Laboratories International, Inc. CRL recently launched its latest Retrogenix Non-Human Protein Library. This non-human protein library will help biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species...

CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica — Oct 10th, 2024

Charles River Laboratories International, Inc. CRL has entered into an agreement with H. Lundbeck A/S (Lundbeck) — a Denmark-based global pharmaceutical company focused on neurological and psychiatric disorders. The collaboration will use Logica, an offering from Charles River and Valo H...

Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call — Oct 16th, 2024

WILMINGTON, Mass., October 16, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2024 financial results on Wednesday, November 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednes...

CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica — Oct 10th, 2024

Charles River Laboratories International, Inc. CRL has entered into an agreement with H. Lundbeck A/S (Lundbeck) — a Denmark-based global pharmaceutical company focused on neurological and psychiatric disorders. The collaboration will use Logica, an offering from Charles River and Valo H...

CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch — Oct 18th, 2024

Charles River Laboratories International, Inc. CRL recently launched its latest Retrogenix Non-Human Protein Library. This non-human protein library will help biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species...

CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch — Oct 18th, 2024

Charles River Laboratories International, Inc. CRL recently launched its latest Retrogenix Non-Human Protein Library. This non-human protein library will help biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species...

Charles River Launches New Retrogenix® Non-Human Protein Library — Oct 17th, 2024

First-in-class in vitro library assesses off-target binding to de-risk in vivo studies WILMINGTON, Mass., October 17, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Retrogenix® Non-Human Protein Library. The non-human p...

CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica — Oct 10th, 2024

Charles River Laboratories International, Inc. CRL has entered into an agreement with H. Lundbeck A/S (Lundbeck) — a Denmark-based global pharmaceutical company focused on neurological and psychiatric disorders. The collaboration will use Logica, an offering from Charles River and Valo H...

Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call — Oct 16th, 2024

WILMINGTON, Mass., October 16, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2024 financial results on Wednesday, November 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednes...

Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call — Oct 16th, 2024

WILMINGTON, Mass., October 16, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2024 financial results on Wednesday, November 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednes...

CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica — Oct 10th, 2024

Charles River Laboratories International, Inc. CRL has entered into an agreement with H. Lundbeck A/S (Lundbeck) — a Denmark-based global pharmaceutical company focused on neurological and psychiatric disorders. The collaboration will use Logica, an offering from Charles River and Valo H...

Charles River Provides Translational Expertise at Neuroscience 2024 — Oct 3rd, 2024

WILMINGTON, Mass., October 03, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18 scientific posters, both independently and collaboratively with clients, at Neuroscience 202...

Charles River Launches New Retrogenix® Non-Human Protein Library — Oct 17th, 2024

First-in-class in vitro library assesses off-target binding to de-risk in vivo studies WILMINGTON, Mass., October 17, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Retrogenix® Non-Human Protein Library. The non-human p...

Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call — Oct 16th, 2024

WILMINGTON, Mass., October 16, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2024 financial results on Wednesday, November 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednes...

Charles River Provides Translational Expertise at Neuroscience 2024 — Oct 3rd, 2024

WILMINGTON, Mass., October 03, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18 scientific posters, both independently and collaboratively with clients, at Neuroscience 202...

Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call — Oct 16th, 2024

WILMINGTON, Mass., October 16, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2024 financial results on Wednesday, November 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednes...

Charles River Launches New Retrogenix® Non-Human Protein Library — Oct 17th, 2024

First-in-class in vitro library assesses off-target binding to de-risk in vivo studies WILMINGTON, Mass., October 17, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Retrogenix® Non-Human Protein Library. The non-human p...

Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease — Oct 2nd, 2024

Logica®, an offering from Charles River and Valo Health, will be leveraged to progress Lundbeck’s research into disorders of the central nervous system WILMINGTON, Mass., October 02, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced an ag...

CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica — Oct 10th, 2024

Charles River Laboratories International, Inc. CRL has entered into an agreement with H. Lundbeck A/S (Lundbeck) — a Denmark-based global pharmaceutical company focused on neurological and psychiatric disorders. The collaboration will use Logica, an offering from Charles River and Valo H...

Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease — Oct 2nd, 2024

Logica®, an offering from Charles River and Valo Health, will be leveraged to progress Lundbeck’s research into disorders of the central nervous system WILMINGTON, Mass., October 02, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced an ag...

Charles River Provides Translational Expertise at Neuroscience 2024 — Oct 3rd, 2024

WILMINGTON, Mass., October 03, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18 scientific posters, both independently and collaboratively with clients, at Neuroscience 202...

Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call — Oct 16th, 2024

WILMINGTON, Mass., October 16, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2024 financial results on Wednesday, November 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednes...

Charles River Provides Translational Expertise at Neuroscience 2024 — Oct 3rd, 2024

WILMINGTON, Mass., October 03, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18 scientific posters, both independently and collaboratively with clients, at Neuroscience 202...

Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease — Oct 2nd, 2024

Logica®, an offering from Charles River and Valo Health, will be leveraged to progress Lundbeck’s research into disorders of the central nervous system WILMINGTON, Mass., October 02, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced an ag...

CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch — Oct 18th, 2024

Charles River Laboratories International, Inc. CRL recently launched its latest Retrogenix Non-Human Protein Library. This non-human protein library will help biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species...

Charles River Provides Translational Expertise at Neuroscience 2024 — Oct 3rd, 2024

WILMINGTON, Mass., October 03, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18 scientific posters, both independently and collaboratively with clients, at Neuroscience 202...

CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch — Oct 18th, 2024

Charles River Laboratories International, Inc. CRL recently launched its latest Retrogenix Non-Human Protein Library. This non-human protein library will help biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species...

CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch — Oct 18th, 2024

Charles River Laboratories International, Inc. CRL recently launched its latest Retrogenix Non-Human Protein Library. This non-human protein library will help biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species...

Charles River Launches New Retrogenix® Non-Human Protein Library — Oct 17th, 2024

First-in-class in vitro library assesses off-target binding to de-risk in vivo studies WILMINGTON, Mass., October 17, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Retrogenix® Non-Human Protein Library. The non-human p...

Charles River Provides Translational Expertise at Neuroscience 2024 — Oct 3rd, 2024

WILMINGTON, Mass., October 03, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18 scientific posters, both independently and collaboratively with clients, at Neuroscience 202...

CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch — Oct 18th, 2024

Charles River Laboratories International, Inc. CRL recently launched its latest Retrogenix Non-Human Protein Library. This non-human protein library will help biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species...

Charles River Provides Translational Expertise at Neuroscience 2024 — Oct 3rd, 2024

WILMINGTON, Mass., October 03, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18 scientific posters, both independently and collaboratively with clients, at Neuroscience 202...

Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease — Oct 2nd, 2024

Logica®, an offering from Charles River and Valo Health, will be leveraged to progress Lundbeck’s research into disorders of the central nervous system WILMINGTON, Mass., October 02, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced an ag...

Charles River Provides Translational Expertise at Neuroscience 2024 — Oct 3rd, 2024

WILMINGTON, Mass., October 03, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18 scientific posters, both independently and collaboratively with clients, at Neuroscience 202...

Charles River Launches New Retrogenix® Non-Human Protein Library — Oct 17th, 2024

First-in-class in vitro library assesses off-target binding to de-risk in vivo studies WILMINGTON, Mass., October 17, 2024--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Retrogenix® Non-Human Protein Library. The non-human p...